HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen

[1]  A. Kamb,et al.  A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo , 2022, Science Translational Medicine.

[2]  Gregory M. Chen,et al.  Decade-long leukaemia remissions with persistence of CD4+ CAR T cells , 2022, Nature.

[3]  G. Coukos,et al.  A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors , 2022, Scientific reports.

[4]  A. Kamb,et al.  Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells , 2022, Journal for ImmunoTherapy of Cancer.

[5]  A. Kamb,et al.  A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy. , 2022, Toxicology and applied pharmacology.

[6]  M. Levings,et al.  Emerging strategies for treating autoimmune disorders with genetically modified Treg cells. , 2022, The Journal of allergy and clinical immunology.

[7]  V. Giudicelli,et al.  IMGT(R), the international ImMunoGeneTics information system(R). , 2022 .

[8]  A. Kamb,et al.  Engineered T cells directed at tumors with defined allelic loss. , 2020, Molecular immunology.

[9]  A. Kamb,et al.  Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen. , 2020, Molecular immunology.

[10]  C. June,et al.  Emerging Cellular Therapies for Cancer. , 2019, Annual review of immunology.

[11]  Charles Swanton,et al.  Abstract LB-A03: Allele specific HLA loss and immune escape in lung cancer evolution , 2018 .

[12]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[13]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[14]  Roland L. Dunbrack,et al.  The Rosetta all-atom energy function for macromolecular modeling and design , 2017, bioRxiv.

[15]  Zhiping Weng,et al.  A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces. , 2016, Protein engineering, design & selection : PEDS.

[16]  Steven G E Marsh,et al.  The IPD-IMGT/HLA Database - New developments in reporting HLA variation. , 2016, Human immunology.

[17]  S. Riddell,et al.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.

[18]  P. Parham,et al.  Direct binding to antigen-coated beads refines the specificity and cross-reactivity of four monoclonal antibodies that recognize polymorphic epitopes of HLA class I molecules. , 2013, Tissue antigens.

[19]  D. Dimitrov,et al.  Soluble Monomeric IgG1 Fc* , 2012, The Journal of Biological Chemistry.

[20]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[21]  Randy J. Read,et al.  Improvement of molecular-replacement models with Sculptor , 2011, Acta crystallographica. Section D, Biological crystallography.

[22]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[23]  Sergey Lyskov,et al.  PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta , 2010, Bioinform..

[24]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[25]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[26]  B. Malissen,et al.  Innate and adaptive immunity: specificities and signaling hierarchies revisited , 2004, Nature Immunology.

[27]  N. Brouwenstijn,et al.  TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning , 2002, International journal of cancer.

[28]  W. Bodmer,et al.  Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2 , 1978, Nature.

[29]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.